Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface

Cancer Immunology, Immunotherapy

Volumn 60, Issue 12, 2011, Pages 1789-1800

  Gubbels, Jennifer A A ^a,e   Gadbaw, Brian ^a   Buhtoiarov, Ilia N ^a   Horibata, Sachi ^a   Kapur, Arvinder K ^a   Patel, Dhara ^a   Hank, Jacquelyn A ^a   Gillies, Stephen D ^b   Sondel, Paul M ^a,c   Patankar, Manish S ^a,d   Connor, Joseph ^a,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b Provenance Biopharmaceuticals Corp   (United States)

^c University of Wisconsin Health   (United States)

^d H4/657 CSC ^*  (United States)

^e AUGUSTANA COLLEGE   (United States)

Author keywords

Cancer; Immune synapse; Immunocytokines; Immunotherapy; Natural killer

Indexed keywords

CD2 ANTIGEN; F ACTIN; FC RECEPTOR; HYBRID PROTEIN; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; TUCOTUZUMAB CELMOLEUKIN;

ALPHA CHAIN; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CELL ACTIVATION; CELL ADHESION; CELL INTERACTION; CELL POLARITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BINDING; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOREACTIVITY; MOLECULAR INTERACTION; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CELL SEPARATION; FEMALE; FLOW CYTOMETRY; GANGLIOSIDES; HUMANS; IMMUNOLOGICAL SYNAPSES; IMMUNOTHERAPY; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICROSCOPY, CONFOCAL; OVARIAN NEOPLASMS; PROTEIN TRANSPORT; RECOMBINANT FUSION PROTEINS;

EID: 82355176013     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1072-9     Document Type: Article

References (59)

1. JM Richards 1989 Therapeutic uses of interleukin-2 and lymphokine-activated killer (LAK) cells Blood Rev 3 110 119 2673443 10.1016/0268-960X(89)90006-4 1:STN:280:DyaL1MznsFOnuw%3D%3D (Pubitemid 19175606)
2. TJ Curiel G Coukos L Zou X Alvarez P Cheng P Mottram M Evdemon-Hogan JR Conejo-Garcia L Zhang M Burow Y Zhu S Wei I Kryczek B Daniel A Gordon L Myers A Lackner ML Disis KL Knutson L Chen W Zou 2004 Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nat Med 10 942 949 15322536 10.1038/nm1093 1:CAS:528: DC%2BD2cXntFSkt7g%3D (Pubitemid 39273735)
3. BH Nelson 2008 The impact of T-cell immunity on ovarian cancer outcomes Immunol Rev 222 101 116 18363996 10.1111/j.1600-065X.2008.00614.x 1:CAS:528:DC%2BD1cXlsFejtrs%3D (Pubitemid 351430376)
4. J Bubenik M Indrova P Perlmann K Berzins O Mach J Kraml A Toulcova 1985 Tumour inhibitory effects of TCGF/IL-2/-containing preparations Cancer Immunol Immunother 19 57 61 3872165 10.1007/BF00199313 1:CAS:528:DyaL2MXksFams7g%3D (Pubitemid 15110997)
5. J Bubenik P Perlmann M Indrova J Simova T Jandlova J Neuwirt 1983 Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL 2)-containing preparations. Preliminary report Cancer Immunol Immunother 14 205 206 6601512 10.1007/BF00205362 1:CAS:528:DyaL3sXktVShsbc%3D (Pubitemid 13117137)
6. SA Rosenberg MT Lotze LM Muul AE Chang FP Avis S Leitman WM Linehan CN Robertson RE Lee JT Rubin, et al. 1987 A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone N Engl J Med 316 889 897 3493432 10.1056/NEJM198704093161501 1:STN:280:DyaL2s7ksVGitA%3D%3D (Pubitemid 17041979)
7. MT Lotze YL Matory AA Rayner SE Ettinghausen JT Vetto CA Seipp SA Rosenberg 1986 Clinical effects and toxicity of interleukin-2 in patients with cancer Cancer 58 2764 2772 3490903 10.1002/1097-0142(19861215)58:12<2764:: AID-CNCR2820581235>3.0.CO;2-Z 1:STN:280:DyaL2s%2FltFaksA%3D%3D (Pubitemid 17232941)
8. HN Lode R Xiang JC Becker SD Gillies RA Reisfeld 1998 Immunocytokines: a promising approach to cancer immunotherapy Pharmacol Ther 80 277 292 9888698 10.1016/S0163-7258(98)00033-3 1:CAS:528:DyaK1cXnsFyjt7g%3D (Pubitemid 28537824)
9. Reisfeld RA, Becker JC, Gillies SD (1997) Immunocytokines: a new approach to immunotherapy of melanoma. Melanoma Res 7(Suppl 2):S99-S106 (Pubitemid 27501633)
10. JP Connor M Felder J Hank J Harter J Gan SD Gillies P Sondel 2004 Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer J Immunother 27 211 219 15076138 10.1097/00002371-200405000-00005 1:CAS:528: DC%2BD2cXksVWgu7c%3D (Pubitemid 39118085)
11. ZC Neal JC Yang AL Rakhmilevich IN Buhtoiarov HE Lum M Imboden JA Hank HN Lode RA Reisfeld SD Gillies PM Sondel 2004 Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy Clin Cancer Res 10 4839 4847 15269160 10.1158/1078-0432.CCR-03-0799 1:CAS:528:DC%2BD2cXlvVegs7Y%3D (Pubitemid 38955538)
12. KL Osenga JA Hank MR Albertini J Gan AG Sternberg J Eickhoff RC Seeger KK Matthay CP Reynolds C Twist M Krailo PC Adamson RA Reisfeld SD Gillies PM Sondel 2006 A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group Clin Cancer Res 12 1750 1759 16551859 10.1158/1078-0432.CCR-05-2000 1:CAS:528:DC%2BD28Xis1Cjs7c%3D
13. EE Johnson HD Lum AL Rakhmilevich BE Schmidt M Furlong IN Buhtoiarov JA Hank A Raubitschek D Colcher RA Reisfeld SD Gillies PM Sondel 2008 Intratumoral immunocytokine treatment results in enhanced antitumor effects Cancer Immunol Immunother 57 1891 1902 18438664 10.1007/s00262-008-0519-0 1:CAS:528: DC%2BD1cXhtFCgu7jE
14. K Wagner P Schulz A Scholz B Wiedenmann A Menrad 2008 The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer Clin Cancer Res 14 4951 4960 18676770 10.1158/1078-0432.CCR-08-0157 1:CAS:528:DC%2BD1cXpt1eis70%3D
15. C Schliemann A Palumbo K Zuberbuhler A Villa M Kaspar E Trachsel W Klapper HD Menssen D Neri 2009 Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2 Blood 113 2275 2283 19005180 10.1182/blood-2008-05-160747 1:CAS:528: DC%2BD1MXjt12ntLY%3D
16. JY Wong DZ Chu LE Williams A Liu J Zhan DM Yamauchi S Wilczynski AM Wu PJ Yazaki JE Shively L Leong AA Raubitschek 2006 A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies Cancer Biother Radiopharm 21 88 100 16706629 10.1089/cbr.2006.21.88 1:CAS:528:DC%2BD28Xks1ajtrs%3D (Pubitemid 43830430)
17. JYC Wong DZ Chu DM Yamauchi LE Williams A Liu S Wilczynski AM Wu JE Shively JH Doroshow AA Raubitschek 2000 A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies Clin Cancer Res 6 3855 3863 11051230 1:CAS:528:DC%2BD3cXotVyktLk%3D
18. MA Lyu R Kurzrock MG Rosenblum 2008 The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell lines Biochem Pharmacol 75 836 846 18082672 10.1016/j.bcp.2007.10.013 1:CAS:528:DC%2BD1cXhsFymtb8%3D
19. SD Gillies EB Reilly KM Lo RA Reisfeld 1992 Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells Proc Natl Acad Sci USA 89 1428 1432 1741398 10.1073/pnas.89.4.1428 1:CAS:528:DyaK38Xhslahs70%3D
20. R Xiang HN Lode CS Dolman T Dreier NM Varki X Qian KM Lo Y Lan M Super SD Gillies RA Reisfeld 1997 Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy Cancer Res 57 4948 4955 9354462 1:CAS:528:DyaK2sXnt12ns7s%3D (Pubitemid 27469007)
21. YJ Ko GJ Bubley R Weber C Redfern DP Gold L Finke A Kovar T Dahl SD Gillies 2004 Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer J Immunother 27 232 239 15076141 10.1097/00002371- 200405000-00008 1:CAS:528:DC%2BD2cXksVWnsr8%3D (Pubitemid 39118088)
22. S Shusterman W London SD Gillies JA Hank S Voss RC Seeger CP Reynolds J Kimball MA Albertini B Wagner J Gan J Eickhoff KD DeSantes SL Cohn T Hecht B Gadbaw RA Reisfeld JM Maris PM Sondel 2010 Anti-tumor activity of hu14.18-IL2 in relapsed/refractory neuroblastoma patients: a Children's Oncology Group (COG) phase II study J Clin Oncol 28 4969 4975 20921469 10.1200/JCO.2009.27.8861 1:CAS:528:DC%2BC3MXisFCntQ%3D%3D
23. Yu AL, Gilman A, Ozkaynak MF, London WB, Kreissman S, Chen H, Smith M, Anderson B, Villablanca J, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM (2010) Chimeric Anti-GD2 antibody with GM-CSF, IL2 and 13-cis retinoic acid for high-risk neuroblastoma: a children's oncology group (COG) phase 3 study. N Engl J Med 363:1324-1334
24. JC Becker JD Pancook SD Gillies K Furukawa RA Reisfeld 1996 T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy J Exp Med 183 2361 2366 8642346 10.1084/jem.183.5.2361 1:CAS:528:DyaK28XjtF2ksLo%3D (Pubitemid 26158928)
25. JD Pancook JC Becker SD Gillies RA Reisfeld 1996 Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2 Cancer Immunol Immunother 42 88 92 8620525 10.1007/s002620050256 1:STN:280:DyaK287ovVyrtg%3D%3D (Pubitemid 26111177)
26. JC Becker JD Pancook SD Gillies J Mendelsohn RA Reisfeld 1996 Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins Proc Natl Acad Sci USA 93 2702 2707 8610104 10.1073/pnas.93.7.2702 1:CAS:528:DyaK28XitVCis7c%3D (Pubitemid 26114312)
27. SD Gillies Y Lan KM Lo M Super J Wesolowski 1999 Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors Cancer Res 59 2159 2166 10232603 1:CAS:528:DyaK1MXjtVWjsbc%3D (Pubitemid 29217680)
28. ZC Neal M Imboden AL Rakhmilevich KM Kim JA Hank J Surfus JR Dixon HN Lode RA Reisfeld SD Gillies PM Sondel 2004 NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy Cancer Immunol Immunother 53 41 52 14504825 10.1007/s00262-003- 0435-2 1:CAS:528:DC%2BD3sXpsVGit7s%3D (Pubitemid 38161180)
29. SD Gillies Y Lan S Williams F Carr S Forman A Raubitschek KM Lo 2005 An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma Blood 105 3972 3978 15692062 10.1182/blood-2004-09- 3533 1:CAS:528:DC%2BD2MXktlSrsbY%3D (Pubitemid 40656145)
30. J Lustgarten J Marks LA Sherman 1999 Redirecting effector T cells through their IL-2 receptors J Immunol 162 359 365 9886407 1:CAS:528: DyaK1MXjt1OksA%3D%3D (Pubitemid 29018941)
31. Buhtoiarov IN, Neal Z, Jan J, Buhtoiarova TN, Hank JA, Yamane B, Rakhmilevich AL, Patankar MS, Gubbels JAA, Reisfeld RA, Gillies SD, Sondel PM (2010) Differential internalization of hu14.18-IL2 by human NK cells and human tumor cells: influence on conjugate formation, cytotoxicity and infiltration into tumors. J Leukoc Biol 89:625-638
32. JA Belisle JA Gubbels CA Raphael M Migneault C Rancourt JP Connor MS Patankar 2007 Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125) Immunology 122 418 429 17617155 10.1111/j.1365-2567.2007.02660.x 1:CAS:528:DC%2BD2sXht12jtrbJ (Pubitemid 47556479)
33. DM Davis I Chiu M Fassett GB Cohen O Mandelboim JL Strominger 1999 The human natural killer cell immune synapse Proc Natl Acad Sci USA 96 15062 15067 10611338 10.1073/pnas.96.26.15062 1:CAS:528:DC%2BD3cXhtFakug%3D%3D (Pubitemid 30019765)
34. T Joshi LP Ganesan C Cheney MC Ostrowski N Muthusamy JC Byrd S Tridandapani 2009 The PtdIns 3-kinase/Akt pathway regulates macrophage-mediated ADCC against B cell lymphoma PLoS ONE 4 e4208 19148288 10.1371/journal.pone. 0004208
35. JA Gubbels J Belisle M Onda C Rancourt M Migneault M Ho TK Bera J Connor BK Sathyanarayana B Lee I Pastan MS Patankar 2006 Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors Mol Cancer 5 50 17067392 10.1186/1476-4598-5-50 (Pubitemid 44742657)
36. JA Gubbels M Felder S Horibata JA Belisle A Kapur H Holden S Petrie M Migneault C Rancourt JP Connor MS Patankar 2010 MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells Mol Cancer 9 11 20089172 10.1186/1476-4598-9-11
37. Zheng X, Wang Y, Wei H, Sun R, Tian Z (2009) LFA-1 and CD2 synergize for the ERK1/2 activation in the NK cell immunological synapse. J Biol Chem 284:21280-21287
38. MJ Robertson KJ Cochran C Cameron JM Le R Tantravahi J Ritz 1996 Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia Exp Hematol 24 406 415 8599969 1:STN:280: DyaK287otValsw%3D%3D (Pubitemid 26098857)
39. LL Lanier JJ Ruitenberg JH Phillips 1988 Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes J Immunol 141 3478 3485 2903193 1:CAS:528:DyaL1MXlvVKm
40. LL Lanier 2008 Up on the tightrope: natural killer cell activation and inhibition Nat Immunol 9 495 502 18425106 10.1038/ni1581 1:CAS:528: DC%2BD1cXkvVOqu74%3D (Pubitemid 351560518)
41. I Waldhauer A Steinle 2008 NK cells and cancer immunosurveillance Oncogene 27 5932 5943 18836474 10.1038/onc.2008.267 1:CAS:528:DC%2BD1cXhtF2msbnE
42. M Rosenstein I Yron Y Kaufmann SA Rosenberg 1984 Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2 Cancer Res 44 1946 1953 6608989 1:CAS:528:DyaL2cXitVOlu7o%3D (Pubitemid 14145137)
43. M Hatakeyama S Minamoto T Taniguchi 1986 Intracytoplasmic phosphorylation sites of Tac antigen (p55) are not essential for the conformation, function, and regulation of the human interleukin 2 receptor Proc Natl Acad Sci USA 83 9650 9654 3099287 10.1073/pnas.83.24.9650 1:CAS:528:DyaL2sXmsFKlsQ%3D%3D (Pubitemid 17223414)
44. M Rickert X Wang MJ Boulanger N Goriatcheva KC Garcia 2005 The structure of interleukin-2 complexed with its alpha receptor Science 308 1477 1480 15933202 10.1126/science.1109745 1:CAS:528:DC%2BD2MXks1eqtr8%3D (Pubitemid 40791303)
45. X Wang M Rickert KC Garcia 2005 Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors Science 310 1159 1163 16293754 10.1126/science.1117893 1:CAS:528:DC%2BD2MXht1WgtLnJ (Pubitemid 41681737)
46. BH Nelson DM Willerford 1998 Biology of the interleukin-2 receptor Adv Immunol 70 1 81 9755337 10.1016/S0065-2776(08)60386-7 1:CAS:528:DyaK1MXmsVKq (Pubitemid 128678836)
47. WC Greene WJ Leonard 1987 Human interleukin 2 receptor (Tac antigen) Methods Enzymol 150 682 700 3123879 10.1016/0076-6879(87)50115-X 1:CAS:528:DyaL1cXhsVynsL4%3D
48. WC Greene WJ Leonard 1986 The human interleukin-2 receptor Annu Rev Immunol 4 69 95 3011033 10.1146/annurev.iy.04.040186.000441 1:CAS:528: DyaL28XktVCltbo%3D
49. HN Lode R Xiang T Dreier NM Varki SD Gillies RA Reisfeld 1998 Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy Blood 91 1706 1715 9473237 1:CAS:528: DyaK1cXht12gtro%3D (Pubitemid 28110336)
50. JE Gestwicki CW Cairo LE Strong KA Oetjen LL Kiessling 2002 Influencing receptor-ligand binding mechanisms with multivalent ligand architecture J Am Chem Soc 124 14922 14933 12475334 10.1021/ja027184x 1:CAS:528: DC%2BD38XovVChsbc%3D (Pubitemid 36014100)
51. JS Orange KE Harris MM Andzelm MM Valter RS Geha JL Strominger 2003 The mature activating natural killer cell immunologic synapse is formed in distinct stages Proc Natl Acad Sci USA 100 14151 14156 14612578 10.1073/pnas.1835830100 1:CAS:528:DC%2BD3sXpsFGitb4%3D (Pubitemid 37499206)
52. AB van Spriel JH Leusen M van Egmond HB Dijkman KJ Assmann TN Mayadas JG van de Winkel 2001 Mac-1 (CD11b/CD18) is essential for Fc receptor-mediated neutrophil cytotoxicity and immunologic synapse formation Blood 97 2478 2486 11290613 10.1182/blood.V97.8.2478 (Pubitemid 32291496)
53. K Krzewski X Chen JL Strominger 2008 WIP is essential for lytic granule polarization and NK cell cytotoxicity Proc Natl Acad Sci USA 105 2568 2573 18258743 10.1073/pnas.0711593105 1:CAS:528:DC%2BD1cXis1Krt7k%3D (Pubitemid 351520554)
54. K Krzewski X Chen JS Orange JL Strominger 2006 Formation of a WIP-, WASp-, actin-, and myosin IIA-containing multiprotein complex in activated NK cells and its alteration by KIR inhibitory signaling J Cell Biol 173 121 132 16606694 10.1083/jcb.200509076 1:CAS:528:DC%2BD28XjsFCgtL8%3D
55. P Lai H Rabinowich PA Crowley-Nowick MC Bell G Mantovani TL Whiteside 1996 Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma Clin Cancer Res 2 161 173 9816103 1:STN:280:DyaK1M%2FjsFSjtw%3D%3D (Pubitemid 26042190)
56. MS Patankar J Yu JC Morrison JA Belisle FA Lattanzio Y Deng NK Wong HR Morris A Dell GF Clark 2005 Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125 Gynecol Oncol 99 704 713 16126266 10.1016/j.ygyno.2005.07.030 1:CAS:528:DC%2BD2MXht1Gitr%2FP (Pubitemid 41686556)
57. DC Delgado J Hank J Kolesar D Lorentzen J Gan S Seo KM Kim S Shusterman SD Gillies RA Reisfeld R Yang B Gadbaw KD DeSantes WB London RC Seeger J Maris PM Sondel 2010 The role for genotypes of killer Ig-like receptors (KIRs), their ligands, and Fcγ receptors on responses of neuroblastoma patients to Hu14.18-IL2: a children's oncology group report Cancer Res 70 9554 9561 20935224 10.1158/0008-5472.CAN-10-2211 1:CAS:528:DC%2BC3cXhsFamur3N
58. G Cartron L Dacheux G Salles P Solal-Celigny P Bardos P Colombat H Watier 2002 Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene Blood 99 754 758 11806974 10.1182/blood.V99.3.754 1:CAS:528:DC%2BD38XhtVals7k%3D (Pubitemid 34525533)
59. WK Weng R Levy 2003 Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma J Clin Oncol 21 3940 3947 12975461 10.1200/JCO.2003.05.013 1:CAS:528:DC%2BD2cXpsVajsb8%3D (Pubitemid 46606207)